Headerlogotextwithshieldsshadowed
Sort by:
Nikmaneshi MR, Firoozabadi B, Mozafari A, Munn LL
A multi-scale model for determining the effects of pathophysiology and metabolic disorders on tumor growth.
Sci Rep. 2020;10(1):3025 - PMID: 32080250 - DOI: 10.1038/s41598-020-59658-0
Millar DG, Ramjiawan RR, Kawaguchi K, Gupta N, Chen J, Zhang S, Nojiri T, Ho WW, Aoki S, Jung K, Chen I, Shi F, Heather JM, Shigeta K, Morton LT, Sepulveda S, Wan L, Joseph R, Minogue E, Khatri A, Bardia A, Ellisen LW, Corcoran RB, Hata AN, Pai SI, Jain RK, Fukumura D, Duda DG, Cobbold M
Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy.
Nat Biotechnol. 2020;38(4):420-425 - PMID: 32042168 - DOI: 10.1038/s41587-019-0404-8
Martin JD, Cabral H, Stylianopoulos T, Jain RK
Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges.
Nat Rev Clin Oncol. 2020;17(4):251-266 - PMID: 32034288 - DOI: 10.1038/s41571-019-0308-z
Chen J, Duda DG
Overcoming sorafenib treatment-resistance in hepatocellular carcinoma: A future perspective at a time of rapidly changing treatment paradigms.
EBioMedicine. 2020;52:102644 - PMID: 32014823 - DOI: 10.1016/j.ebiom.2020.102644
Mpekris F, Voutouri C, Baish JW, Duda DG, Munn LL, Stylianopoulos T, Jain RK
Combining microenvironment normalization strategies to improve cancer immunotherapy.
Proc Natl Acad Sci U S A. 2020;117(7):3728-3737 - PMID: 32015113 - DOI: 10.1073/pnas.1919764117
Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, Fearon D, Greten FR, Hingorani SR, Hunter T, Hynes RO, Jain RK, Janowitz T, Jorgensen C, Kimmelman AC, Kolonin MG, Maki RG, Powers RS, Puré E, Ramirez DC, Scherz-Shouval R, Sherman MH, Stewart S, Tlsty TD, Tuveson DA, Watt FM, Weaver V, Weeraratna AT, Werb Z
A framework for advancing our understanding of cancer-associated fibroblasts.
Nat Rev Cancer. 2020;20(3):174-186 - PMID: 31980749 - DOI: 10.1038/s41568-019-0238-1
Flores-Toro JA, Luo D, Gopinath A, Sarkisian MR, Campbell JJ, Charo IF, Singh R, Schall TJ, Datta M, Jain RK, Mitchell DA, Harrison JK
CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.
Proc Natl Acad Sci U S A. 2020;117(2):1129-1138 - PMID: 31879345 - DOI: 10.1073/pnas.1910856117
Seano G, Jain RK
Vessel co-option in glioblastoma: emerging insights and opportunities.
Angiogenesis. 2020;23(1):9-16 - PMID: 31679081 - DOI: 10.1007/s10456-019-09691-z
Arvanitis CD, Ferraro GB, Jain RK
The blood-brain barrier and blood-tumour barrier in brain tumours and metastases.
Nat Rev Cancer. 2020;20(1):26-41 - PMID: 31601988 - DOI: 10.1038/s41568-019-0205-x
Gerstner E, Emblem KE, Chang K, Vakulenko-Lagun B, Yen YF, Beers AL, Dietrich J, Plotkin SR, Catana C, Hooker JM, Duda DG, Rosen B, Kalpathy-Cramer J, Jain RK, Batchelor T
Bevacizumab reduces permeability and concurrent temozolomide delivery in a subset of patients with recurrent glioblastoma.
Clin Cancer Res. 2020;26(1):206-212 - PMID: 31558474 - DOI: 10.1158/1078-0432.CCR-19-1739
Leone JP, Duda DG, Hu J, Barry WT, Trippa L, Gerstner ER, Jain RK, Tan S, Lawler E, Winer EP, Lin NU, Tolaney SM
A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases.
Breast Cancer Res Treat. 2020;179(1):113-123 - PMID: 31541381 - DOI: 10.1007/s10549-019-05445-z
11